Earlier this month, the Indian Council of Medical Research (ICMR) director stressed that with the first dose of the Covishield vaccine “good levels” of antibodies are.
PathShodh received the license to manufacture the test for sale from the Central Drugs Standard Control Organisation, after careful examination and validation from the Translational Health Science and Technology Institute, as per the requirements of the Indian Council of Medical Research (ICMR).
The first batch of DRDO-developed anti-Covid drug 2-DG (2-deoxy-D-glucose) was launched on Monday to treat patients suffering from the deadly disease. The
India s DCGI allows use of oxygen dependence-lowering Covid-19 drug pharmaceutical-business-review.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmaceutical-business-review.com Daily Mail and Mail on Sunday newspapers.
09NEW DELHI, May 8: The Drug Controller General of India (DCGI) has approved the emergency use of DRDO’s anti-COVID-19 therapeutic oral drug 2-deoxy-D-glucose (2-DG) as adjunct therapy in moderate to severe COVID-19 patients.
On May 1, the DCGI granted permission for ‘Emergency Use’ of this drug. Being a generic molecule and analogue of glucose, it can be easily produced and made available in plenty in the country.
The drug comes in powder form in sachet, which is taken orally by dissolving it in water. It accumulates in the virus infected cells and prevents virus growth by stopping viral synthesis and energy production. Its selective accumulation in virally infected cells makes this drug unique, the DRDO said in a statement today.